Targets › TSPO
11 programs from 10 companies in 16 trials: 9 Phase 1, 7 Phase 2; Neurology, Other, Cardiovascular; next expected readout Nov 2026.
Can bind protoporphyrin IX and may play a role in the transport of porphyrins and heme (By similarity). Promotes the transport of cholesterol across mitochondrial membranes and may play a role in lipid metabolism, but its precise physiological role is controversial. (UniProt, P30536)
Open in Phaseline: the race on TSPO, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Columbia University | 11C-ER176 TSPO radioligand | TSPO | Phase 2 | Alzheimer Disease | Dec 2026 |
| Hospices Civils de Lyon | [18F]DPA-714 TSPO (translocator protein) PET tracer for imaging neuroinflammation | TSPO | Phase 2 | CAROTID STENOSIS | Dec 2026 |
| Massachusetts General Hospital | [11C]PBR28 TSPO PET imaging agent | TSPO | Phase 2 | Chronic Pain; Blast Injury | Aug 2027 |
| Imperial College London | XBD173 TSPO (18 kDa Translocator Protein) agonist | TSPO | Phase 2 | Heathly Volunteers | Sep 2028 |
| St. Jude Children's Research Hospital | [18F]DPA-714 TSPO PET imaging tracer | TSPO | Phase 2 | Brain Tumor | Oct 2035 |
| University of California, Davis | [18F]DPA-714 TSPO (translocator protein) PET imaging tracer | TSPO | Phase 1 | Epilepsy, Post-Traumatic | Nov 2026 |
| University of Alabama at Birmingham | [F-18]AV-1451 Translocator protein (TSPO) ligand for PET imaging | TSPO | Phase 1 | Idiopathic Pulmonary Fibrosis; Alzheimer Disease | Jun 2027 |
| University of Alabama at Birmingham | [F-18]DPA-714 TSPO (18 kDa translocator protein) ligand PET tracer | TSPO | Phase 1 | Fibromyalgia; Parkinson Disease | Apr 2028 |
| The University of Texas Health Science Center, Houston | [11C]PBR-28 TSPO (translocator protein) PET radiotracer for imaging microglial activation | TSPO | Phase 1 | Neuropsychiatric Syndromes | Aug 2028 |
| University of North Carolina, Chapel Hill | [18F] PBR111 Translocator protein (TSPO) PET imaging tracer | TSPO | Phase 1 | Concussion, Brain | Aug 2028 |
| Yale University | [11C]PBR28 TSPO radiotracer for imaging microglial activation and neuroimmune status | TSPO | Phase 1 | HIV Associated Neurocognitive Disorder | Dec 2028 |
Alzheimer Disease (3) Idiopathic Pulmonary Fibrosis (2) CAROTID STENOSIS (1) Brain Tumor (1) Chronic Pain (1) Blast Injury (1) Concussion, Brain (1) Epilepsy, Post-Traumatic (1) HIV Associated Neurocognitive Disorder (1) Neuropsychiatric Syndromes (1) Fibromyalgia (1) Parkinson Disease (1)
small molecule (11)
University of Alabama at Birmingham (2) Hospices Civils de Lyon (1) St. Jude Children's Research Hospital (1) Massachusetts General Hospital (1) Columbia University (1) University of North Carolina, Chapel Hill (1) University of California, Davis (1) Yale University (1) The University of Texas Health Science Center, Houston (1) Imperial College London (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.